Register for our free email digests:
Latest From Brainsway Ltd.
The Helsinki-based company had expected stroke rehabilitation to be the first FDA-cleared indication for its Navigated Brain Therapy system, but while more data is collected for that program, it is pursuing a 510(k) clearance for NBS to treat major depressive disorder and plans to build a US salesforce to market NBS for therapeutic indications.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The registry will collect data from more than 6,000 depression patients treated with transcranial magnetic stimulation at more than 100 different treatment facilities in the US to better understand how the therapy benefits patients in the "real world."
Noninvasive electromagnetic neurostimulation devices designed to improve peoples’ memory or learning abilities currently show some promise, but also feature unknowns surrounding their mechanisms of actions and long term effects, said speakers at an FDA workshop on the devices.
- Medical Devices
- Therapeutic Areas
- Neurology, Nervous System
- Middle East
- Parent & Subsidiaries
- Brainsway Ltd.
- Senior Management
Yaacov Michlin, CEO
Aron Tendler, MD, CMO
- Contact Info
Phone: 2 581-3140
Bynet Bldg., 1st. Fl.
19 Hartum St.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.